Research Advocate, Annie Ellis, recently attended the Biennial Ovarian Cancer Research Symposium presented by the Rivkin Center for Ovarian Cancer and the American Association for Cancer Research. Read her report, check out a poster on Beyond RECIST 1.1 and a poster on MAGENTA-Making Genetic Testing More Accessible.
On September 13th, Abcodia Incorporated, the makers of the ROCA Test, released this statement*, following the safety guidance put out by the FDA last week. ROCA Test sales are now suspended in the United States. *Note: The original publication of this article linked to an article that has since been archived. For more updated information, please visit … Continued
Meet Researcher Kris Wood, PhD! Q&A with Kris Wood, PhD Duke University 2015 Liz Tilberis Award OCRFA: Tell me about yourself. Kris Wood: I grew up in Georgetown, KY, a rural town in the central part of the state. My family lived in a house on my grandfather’s farm, which was a wonderful place to … Continued
(August 16, 2016) While primary cytoreductive surgery followed by chemotherapy is the standard of care for newly diagnosed women with advanced ovarian cancer, newly issued practice guidelines suggest that some patients may benefit more from first-line neoadjuvant chemotherapy (NACT) and followed by surgery. Last week, the Society for Gynecologic Oncology (SGO) and the American Society … Continued
(Aug 1. 2016) Results of a study reported last month in Cancer show that routine referral of women at high risk for ovarian cancer to genetic counseling promotes genetic testing and prophylactic surgery. Guidelines recommend genetic counseling and testing for women who have a pedigree suggestive of an inherited susceptibility for ovarian cancer (for example, … Continued
(July 28, 2016) A study published recently in JAMA Oncology showed that CA-125 tests and CT scans are routinely used in ovarian cancer surveillance testing, even though evidence has shown there is no clinical benefit to using these tests. There is no consensus on how to follow a patient in remission from ovarian cancer in … Continued
Dr. Anne Reb at Walter Reed National Military Medical Center is currently looking for participants in her research study for women who have been diagnosed with Stage 3 or 4 ovarian cancer and have completed their primary treatment within the last four months and have no clinical evidence of disease. The study will teach you … Continued
(July 18, 2016) The first randomized phase III clinical trial to compare irinotecan and cisplatin with paclitaxel plus carboplatin in patients with clear cell carcinoma (CCC) of the ovary found no significant survival benefit between the groups. The findings of the study, which was conducted in Japan, were reported in the Journal of Clinical Oncology. … Continued
(July 6, 2016) Gynecologic Oncology recently published a study that found that, although surgery leads to longer survival rates, many ovarian cancer patients are not undergoing surgery, and some are not being treated at all. The researchers analyzed data from more than 210,000 women diagnosed with ovarian cancer in the United States between 2003 and … Continued
Every year cancer researchers and doctors gather at several professional meetings to present and discuss the latest and most important advances in basic, translational and clinical cancer research. OCRF Scientific Advisory Committee member Douglas A. Levine, MD, highlighted research relevant to ovarian cancer patients presented at the American Society of Clinical Oncology (ASCO), as well … Continued
(June 23, 2016) The Journal of Clinical Oncology recently published a study on the role of oral contraceptives (OC) on ovarian cancer prevention. The study, which analyzed data from 21 studies with 5, 584 cases of ovarian cancer, concluded that OC reduced the risk of a variety of invasive ovarian cancers. The risk of developing … Continued
Highlights from the June 2016 American Society of Clinical Oncology (ASCO) Annual Meetingby Susan Leighton, Ovarian Cancer Survivor and Research Advocate Since the first time I attended ASCO I have seen the number of abstracts presented about ovarian cancer increase significantly as understanding of the disease has expanded. No longer do we hear the one size fits … Continued
Get email updates about research news, action alerts, and ways to join the fight.
